Skip to content
OpenCapital
Get started

Bio-Rad Laboratories BIO Lease Liability Payments - Due Year Two

Lease Liability Payments - Due Year Two at other companies

Abbott logo
AbbottABT
$254M+0.8%
Idexx Laboratories logo
Idexx LaboratoriesIDXX
——

Other financials

Income statement

See full
Revenue$592.1M+1.1%
Gross profit$309.4M+1.1%
Operating income$34.1M+43.9%
Net income-$527.1M-924%
EPS (diluted)-$19.55-954%

Balance sheet

See full
Cash & equivalents$509.0M-2.7%
Total debt$987.3M-28.4%
Total equity$6.9B+2.6%
Total assets$9.8B+2.8%

Cash flow

See full
Operating cash flow$108.1M-16.8%
CapEx$30.0M-12.8%
Free cash flow$78.1M-18.2%

Valuation

See full
Market cap$7.56B+10.3%
Enterprise value$8.04B+4.2%
P/E44.8×—
P/S2.9×+0.2×

Profitability

See full
Gross margin51.9%-1.6pp
Operating margin8.8%-3.1pp
Net margin6.5%+3.4pp
FCF margin13.8%-0.2pp

Returns & leverage

See full
Return on equity2.5%+1.3pp
Debt / equity0.1×-0.1×
Current ratio3.2×-2.8×

Where this comes from

Reported directly by Bio-Rad Laboratories in its filing.

Tagged under the XBRL concept us-gaap:FinanceLeaseLiabilityPaymentsDueYearTwo.

The official record: Bio-Rad Laboratories’s 10-Q, filed April 30, 2026, on SEC EDGAR. View the filing →

Ask your AI about Bio-Rad Laboratories's lease liability payments - due year two.

Connect your AI assistant and compare it to peers, right in your chat.

Connect your AI
Harbor at dusk
Claude

Questions, answered.

What is Bio-Rad Laboratories's lease liability payments - due year two?
Bio-Rad Laboratories (BIO) reported lease liability payments - due year two of $1.1M in Q1 2026.
How has Bio-Rad Laboratories's lease liability payments - due year two changed year-over-year?
Bio-Rad Laboratories's lease liability payments - due year two decreased by 0.0% year-over-year, from $1.1M to $1.1M.
What does lease liability payments - due year two mean?
This metric identifies the total cash payments required for operating and finance leases in the second year following the current balance sheet date. It helps investors forecast long-term fixed cost commitments and cash flow requirements. It is essential for modeling the company's future solvency and operational leverage.